Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04414163

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Extranodal NK/T-cell Lymphoma Clinical Trial

Official title:
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Clinical Trial Summary

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Clinical Trial Description

IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04414163
Study type Interventional
Source ImmuneOncia Therapeutics Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 28, 2020
Completion date February 28, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04509466 - Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Phase 1/Phase 2
Not yet recruiting NCT04676789 - Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL Phase 2
Active, not recruiting NCT01991158 - GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma Phase 2
Active, not recruiting NCT03363555 - SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Phase 2
Recruiting NCT04405375 - GPED Regimen for Relapsed/Refractory or Advanced ENKTCL Phase 2
Recruiting NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02631239 - MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Phase 3
Recruiting NCT01667302 - Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Phase 2
Terminated NCT01667289 - Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma Phase 2
Not yet recruiting NCT04338282 - Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma Phase 2
Recruiting NCT05978141 - A Registry for People With T-cell Lymphoma
Completed NCT02386813 - International Extranodal NK/T-cell Lymphoma Project N/A
Recruiting NCT01921790 - Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2